NasdaqGS - Delayed Quote • USD
BioNTech SE (BNTX)
At close: April 25 at 4:00 PM EDT
Pre-Market: 7:00 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 15 | 14 |
| Avg. Estimate | -1.06 | -2.04 | -2.08 | -1.46 |
| Low Estimate | -2.94 | -3.19 | -8.29 | -6.12 |
| High Estimate | 1.26 | -0.94 | 4.25 | 4.5 |
| Year Ago EPS | 2.25 | -0.83 | 4.1 | -2.08 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 9 | 18 | 16 |
| Avg. Estimate | 457.54M | 169.32M | 3B | 2.97B |
| Low Estimate | 171.95M | 107.03M | 2.3B | 1.75B |
| High Estimate | 1.35B | 307.81M | 4.47B | 4.22B |
| Year Ago Sales | 1.4B | -- | 4.09B | 3B |
| Sales Growth (year/est) | -67.30% | -- | -26.70% | -0.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.16 | -1.01 | -0.1 | 2.59 |
| EPS Actual | 2.25 | -0.83 | 0.73 | 2.03 |
| Difference | 2.09 | 0.18 | 0.83 | -0.56 |
| Surprise % | 1,306.20% | 17.80% | 830.00% | -21.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.06 | -2.04 | -2.08 | -1.46 |
| 7 Days Ago | -0.94 | -1.88 | -1.62 | -1.38 |
| 30 Days Ago | -0.98 | -1.95 | -0.47 | -0.03 |
| 60 Days Ago | -0.33 | -1.96 | 1.04 | 1.47 |
| 90 Days Ago | -0.08 | -1.93 | 1.22 | 1.23 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | 1 | 2 | 4 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | BNTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -147.10% | -- | -- | 2.60% |
| Next Qtr. | -145.80% | -- | -- | 13.40% |
| Current Year | -150.70% | -- | -- | 5.20% |
| Next Year | 29.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -33.82% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -35.55% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/17/2024 |
| Maintains | UBS: Neutral to Neutral | 3/27/2024 |
| Maintains | JP Morgan: Underweight to Underweight | 3/22/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 3/21/2024 |
| Reiterates | Canaccord Genuity: Buy to Buy | 3/21/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 2/28/2024 |
Related Tickers
MRNA Moderna, Inc.
106.18
-2.45%
NVAX Novavax, Inc.
3.9500
-4.82%
CVAC CureVac N.V.
2.3100
-7.97%
REGN Regeneron Pharmaceuticals, Inc.
890.68
-1.75%
VRTX Vertex Pharmaceuticals Incorporated
397.70
-0.76%
NTLA Intellia Therapeutics, Inc.
20.02
-5.43%
BMRN BioMarin Pharmaceutical Inc.
82.17
-9.90%
CRSP CRISPR Therapeutics AG
53.73
-3.45%
SRPT Sarepta Therapeutics, Inc.
127.39
+2.53%
VKTX Viking Therapeutics, Inc.
68.86
+5.82%